# Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Canonical URL: https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-appointment-of-kartik-krishnan-m-d-ph-d-as-chief-medical-officer
Ticker: KTTA
Company: Pasithea Therapeutics
Source: Pasithea Therapeutics
Published: 2026-05-04 11:01 EST
Original Source URL: https://ir.pasithea.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-21 11:00 EST — [Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-presentation-of-pas-004-data-to-european-society-99db076a) — Source: Pasithea Therapeutics
- 2026-07-08 11:02 EST — [Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-participation-in-b-riley-securities-mind-muscle--c2ef8757) — Source: Pasithea Therapeutics
- 2026-06-30 11:00 EST — [Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-positive-interim-phase-1-advanced-cancer-study-d-e066723c) — Source: Pasithea Therapeutics
- 2026-06-16 11:00 EST — [Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-amendments-to-clinical-study-protocol-for-phase--66feaf01) — Source: Pasithea Therapeutics
- 2026-06-15 11:02 EST — [Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-exhibit-at-children-s-tumor-foundation-2026-nf-c-c12a7718) — Source: Pasithea Therapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)